KUOPIO

EQS-News: CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing

Retrieved on: 
Tuesday, September 20, 2022
Safety, Infection, Immunodeficiency, Development, Human, COVID-19, Risk, AAV, Disease, FDA, Research, Bioreactor, Severe acute respiratory syndrome coronavirus 2, Company, Business Finland, Patient, RSV, Laboratory, Transfection, Technology, Vaccine, RCA, EUR, University, GMP, Pharmaceutical industry

Under the agreement, CEVEC has granted ROKOTE Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.

Key Points: 
  • Under the agreement, CEVEC has granted ROKOTE Laboratories Finland Ltd non-exclusive rights to use the CAP Ad platform for the manufacturing of adeno-based vaccines for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV infections.
  • We are very pleased that ROKOTE Laboratories Finland Ltd will build on the CAP Ad Technology and we are proud that we can contribute to combating the ongoing COVID-19 pandemic with a technology that makes a real difference in vaccine safety, said Dr. Nicole Faust, Chief Executive Officer of CEVEC.
  • Our CAP Ad Technology ensures that the risk of potential adverse effects due to contaminating replication-competent adenovirus is as low as possible.
  • The CAP Ad Technology is an innovative technology platform developed by CEVEC for the scalable production of RCA-free adenoviral vectors for gene therapy applications and vaccines.

Orion is planning to refocus its R&D – in the future focus would be on cancer and pain

Retrieved on: 
Thursday, March 24, 2022
Lists of diseases, Alzheimer's disease, Sale, Investment, Marketing, Retirement, Growth, Neurodegeneration, Research, Cancer, Orion, Pain, Pain management, Employment, Chronic pain, Person, Animal, Prostate cancer, R, Pharmacy, Patient, Bayer, Fine chemical, Pharmaceutical industry

The company would invest in the research and development of new proprietary drugs in two therapy areas, cancer and pain.

Key Points: 
  • The company would invest in the research and development of new proprietary drugs in two therapy areas, cancer and pain.
  • The possible changes planned would target the therapy and research areas in which Orion would no longer invest in the future.
  • Orions R&D function is planning to refocus its efforts on the development of new proprietary products from several therapy areas to two, cancer diseases and pain.
  • For many years, Orion has also conducted R&D projects associated with pain management in the therapy area of neurological diseases.

Kamux to move business from Varkaus to other showrooms in the region, closing down in Varkaus

Retrieved on: 
Wednesday, December 22, 2021
City, EUR, Nasdaq Helsinki, Sale, Growth, Car dealership

HELSINKI, Dec. 22, 2021 /PRNewswire/ -- Kamux will relocate the business activity of its showroom in Varkaus to other Kamux showrooms in the region, and the Varkaus showroom will be closed down.

Key Points: 
  • HELSINKI, Dec. 22, 2021 /PRNewswire/ -- Kamux will relocate the business activity of its showroom in Varkaus to other Kamux showrooms in the region, and the Varkaus showroom will be closed down.
  • The Varkaus showroom business will be transferred to other dealerships around the beginning of 2022.
  • Kamux Corporation is a retail chain specializing in the sale of used cars and related integrated services that has grown rapidly.
  • Kamux combines online shopping with an extensive showroom network to provide its customers with a great service experience anytime, anywhere.

Janne Kouri, CEO and Founder of Non-profit NextStep, Brings Famed Finnish Long Drink to the US Market

Retrieved on: 
Wednesday, December 15, 2021
Wine & Spirits, Other Consumer, Supermarket, Philanthropy, Women, Men, Retail, Fund Raising, Foundation, Consumer, Restaurant, Bar, Face, Courage, Stock, Paralysis, Culture, Rock paper scissors, RTD, Kouri, Light, SISU, Multimedia, Energy drink, Next Step, Long drink, Coffee, Lonkero

Finnish-American Founder of non-profit NextStep , Janne Kouri, brings Loncaro , the first authentic ready-to-drink (RTD) Long Drink recipe to the US in March 2022.

Key Points: 
  • Finnish-American Founder of non-profit NextStep , Janne Kouri, brings Loncaro , the first authentic ready-to-drink (RTD) Long Drink recipe to the US in March 2022.
  • Loncaro will be one of the first two authentic Long Drinks to help grow the category in the US.
  • After the Los Angeles launch, Kouri will focus on the rest of California, and neighboring states, before expanding nationally.
  • Loncaros 2022 product launch will first include the authentic Long Drink flavor from Kuopio, Finland, followed by three additional SKUs in 2023.

L2 Fire Safety, Finland's Top Fire Engineering Firm, Completes Brand Integration into Jensen Hughes

Retrieved on: 
Thursday, December 16, 2021
Consultant, Government, Jensen Hughes, CEO, Safety, Transport, L2, Leadership, Investment, Griffin, Partnership, Risk management

L2 Fire Safety specializes in structural fire engineering, compliance regulations, fire engineering life cycle design and performance-based design services for large, complex projects.

Key Points: 
  • L2 Fire Safety specializes in structural fire engineering, compliance regulations, fire engineering life cycle design and performance-based design services for large, complex projects.
  • Jensen Hughes is pleased to announce that L2 hasbeen rebranded to the Jensen Hughes name and has been migrated into the Jensen Hughes Europe website.
  • Please visit the new localized Finland pages on Jensen Hughes Europe to explore the full range of services provided by the Jensen Hughes offices in Helsinki, Tampere, Turku, Oulu, and Kuopio.
  • "We are pleased to rebrand L2 to Jensen Hughes.

L2 Fire Safety, Finland's Top Fire Engineering Firm, Completes Brand Integration into Jensen Hughes

Retrieved on: 
Thursday, December 16, 2021
Consultant, Government, Jensen Hughes, CEO, Safety, Transport, L2, Leadership, Investment, Griffin, Partnership, Risk management

L2 Fire Safety specializes in structural fire engineering, compliance regulations, fire engineering life cycle design and performance-based design services for large, complex projects.

Key Points: 
  • L2 Fire Safety specializes in structural fire engineering, compliance regulations, fire engineering life cycle design and performance-based design services for large, complex projects.
  • Jensen Hughes is pleased to announce that L2 hasbeen rebranded to the Jensen Hughes name and has been migrated into the Jensen Hughes Europe website.
  • Please visit the new localized Finland pages on Jensen Hughes Europe to explore the full range of services provided by the Jensen Hughes offices in Helsinki, Tampere, Turku, Oulu, and Kuopio.
  • "We are pleased to rebrand L2 to Jensen Hughes.

Exothera announces the appointment of Hanna Lesch as Chief Technology Officer

Retrieved on: 
Wednesday, October 27, 2021
Research, Molecular medicine, CDMO, University, Industry, CA, Contract, University of Eastern Finland, GMP, Cell, CEO, Multimedia, FKD, Solution, Doctor of Philosophy, Vaccine, Pharmaceutical industry

JUMET, Belgium, Oct. 27, 2021 /PRNewswire/ -- Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), today announced that it has appointed Hanna Lesch as Chief Technology Officer. Hanna's extensive experience in cell and gene therapies will further extend Exothera's capabilities in designing high-quality, cost-effective viral vector processes tailored to the requirements of its customers' particular molecules.

Key Points: 
  • JUMET, Belgium, Oct. 27, 2021 /PRNewswire/ -- Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), today announced that it has appointed Hanna Lesch as Chief Technology Officer.
  • Hanna has dedicated her career to gene therapy and has held several director positions including leading research and development at FKD Therapies, Kuopio Center for Cell & Gene Therapy.
  • Commenting on her appointment, Hanna Lesch said : "I have always enjoyed working in the translational field, where early biological insights convert into therapy.
  • Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing.

Most Powerful .NET Charting Library New Version Now Available for Free Trial | LightningChart®

Retrieved on: 
Wednesday, June 30, 2021

KUOPIO, Finland, June 30, 2021 /PRNewswire-PRWeb/ --LightningChart has been the pioneer in developing high-performance charting libraries for NET and JavaScript.

Key Points: 
  • KUOPIO, Finland, June 30, 2021 /PRNewswire-PRWeb/ --LightningChart has been the pioneer in developing high-performance charting libraries for NET and JavaScript.
  • Recently, LightningChart just released the newest version for .NET, its version 10.1.1 achieves what other commercial and open-sourced charting libraries cannot do regarding real-time and high-performance data visualization using an extremely low consumption of device resources.
  • The LightningChart team based in Kuopio, Finland has been able to launch this unbeatable version 10.1.1 which represents a major breakthrough for the scientific data visualization industry.
  • Our mission is to produce the absolute best performance charts for .NET and JavaScript for advanced applications in demanding industries."

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Retrieved on: 
Thursday, June 17, 2021
Hallucinations, Amines, Entheogens, Psychoactive drugs, Ayahuasca, N,N-Dimethyltryptamine, Hallucinogen, Pharmacokinetics, Psychedelic drug, Life sciences

The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure.

Key Points: 
  • The planned Phase 1 study will investigate the safety, tolerability and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure.
  • Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients.
  • While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies, said Christopher J. Moreau, CEO of Algernon pharmaceuticals.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Finnish researchers introduce a nasal COVID vaccine

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Medicine, Health, Vaccination, Virology, Vaccines, Vaccine, Adenoviridae, COVID-19 vaccines, Clinical trials, Virus, COVID-19 vaccine

JOENSUU, Finland, March 8, 2021 /PRNewswire/ -- Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID.

Key Points: 
  • JOENSUU, Finland, March 8, 2021 /PRNewswire/ -- Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID.
  • The vaccine is based on research carried out at the University of Helsinki and the University of Eastern Finland.
  • The vaccine uses a safe adenovirus carrier that contains a cloned DNA strand, which causes nasopharyngeal cells to produce the virus protein which, in turn, produces a response to the vaccine.
  • After being granted a marketing authorisation, the vaccine could ensure Finnish and European security of supply, and vaccine self-sufficiency.